Replimune is creating a new class of oncolytic immunotherapy designed to ignite a powerful immune response to treat cancer and vaccinate against future relapse. Replimune is a biotechnology firm that develops oncolytic immuno-gene therapies to treat cancer.Number of Partnerships: 10
